George Kumar, Senior Director of Medical Diagnostics, Pan Tumor and GI Cancers at AstraZeneca, shared an article by Yang Bai, Albert S. Agustinus et, al published on AACR journals, on LinkedIn, adding:
“New Insights in Triple-Negative Breast Cancer (TNBC).
Epigenetic regulation of chromosomal instability by EZH2 methyltransferase.
Triple-negative breast cancer (TNBC) remains one of the most aggressive and hardest-to-treat breast cancers, largely due to its high risk of metastasis. A new study from Vivek Mittals lab at Weill Cornell Medicine, published in Cancer Discovery, reveals that the enzyme EZH2 drives abnormal cell division in TNBC – fueling its spread to distant organs.
Excitingly, researchers found that blocking EZH2 with targeted drugs can restore orderly cell division and prevent metastasis. Unlike strategies that push tumor cells into even greater chromosomal chaos, this approach reins in instability at its source.
The work not only highlights a potential new use for EZH2 inhibitors such as tazemetostat, but also opens the door to trials in other cancers marked by chromosomal instability (e.g., lung adenocarcinoma).
This study provides hope that restoring balance – not just breaking cells further – may be the key to stopping aggressive cancers in their tracks.
Figure Courtesy: Dr. Shelley Yang Bai: Weill Cornell Medical Center. NY, NY, United States.”
Title: Epigenetic regulation of chromosomal instability by EZH2 methyltransferase
Authors: Yang Bai, Albert S. Agustinus, Shira Yomtoubian, Cem Meydan, Dylan R. McNally, Liron Yoffe, Melissa J. Hubisz, Marvel Tranquille, Sneha Pramod, Christy Hong, Magdalena L. Plasilova, Aakanksha R. Kapoor, Arshdeep Singh, Henry Withers, Lukas E. Dow, Ashley M. Laughney, Bhavneet Bhinder, Olivier Elemento, Ari M. Melnick, Samuel F. Bakhoum, Vivek Mitta
Read the full article on AACR journals.
Read more posts featuring George Kumar on OncoDaily.